Eli Lilly Stock’s Next Climb Runs Through A Pill, Not Just An Injection

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

Eli Lilly (LLY) stock has returned 85% over the past year, trades about 4% below its 52-week high, and has produced nine gains of more than 30% inside two months since 2018. At that level the question is not whether the incretin franchise works, but what upside the price has not already taken. The company’s own second-quarter 2026 disclosure points at an answer, and it is not in the pipeline.

Eight Thousand Prescribers Became Thirty-Six Thousand

The medicine is orforglipron, Lilly’s oral GLP-1, and its constraint was never efficacy. It was reach: doctors who had never written a pill for obesity, and patients with no coverage for one. Three months ago Lilly counted just over 8,000 prescribers for the drug. The count is now 36,000. Management says the last week of July ran at close to double the volume of a month earlier, with nearly one in four new patient starts going to the oral. An analyst has called the U.S. launch curve slower than anticipated. Prescriber breadth moved first, and it moved a long way.

Medicare Opened The Obesity Door On July First

The second change is who pays. The Medicare GLP-1 Bridge program launched on July 1, giving 20 million eligible Americans coverage for obesity GLP-1s at $50 a month. Access is what actually binds here: management puts obesity treatment utilization in the mid-single digits, and reckons 60% to 70% of those arriving had no coverage before. About 80% of the people getting treatment under the program are on an injectable, which is exactly the point. Coverage widens the whole obesity market first; the pill takes its share of a bigger market after.

The numbers so far are an injectable story. Revenue in the second quarter of 2026 was $23.0 billion, and Mounjaro and Zepbound alone produced $14.9 billion of it. That volume has also reset the profit line: operating margin over the trailing twelve months, at 50%, runs well above its own three-year average of 39%. Growth that lands in margin rather than only in volume is one of the qualities the Trefis High Quality Portfolio holds its names to.

The Upside Case Now Has To Show Up In Guidance

So, the honest size of it: against $79.7 billion of trailing twelve-month revenue, a launch still counted in prescribers does not re-rate a company this large. What it does is lengthen the runway. Orforglipron is a small molecule that can be produced at scale, it sits under regulatory review in more than 40 additional countries, and Lilly expects a global rollout in all major markets in 2027. The payoff is more raises like the one just made: Lilly lifted the low end of its 2026 revenue range by $3 billion and the high end by $2 billion, to $85 billion to $87 billion. One analyst read that same range as implying a slower second half. The number to watch is the next revision, once the July access change has a full reporting period behind it, and that is precisely the test a guidance-momentum screen is built for.

Finding Winners Is Half The Job, Keeping The Gains Is The Other

Spotting the opportunity is the enjoyable half of investing, keeping what it earns is the half that compounds. Either way, a position that has grown large enough to matter is worth sizing deliberately rather than by accident. What a position that size would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.